GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Adicon Holdings Ltd (HKSE:09860) » Definitions » Valuation Rank

Adicon Holdings (HKSE:09860) Valuation Rank


View and export this data going back to 2023. Start your Free Trial

What is Adicon Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Adicon Holdings Valuation Rank Related Terms

Thank you for viewing the detailed overview of Adicon Holdings's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Adicon Holdings Business Description

Traded in Other Exchanges
Address
No. 208, Zhenzhong Road, West Lake, Zhejiang, Hangzhou, CHN
Founded in 2004 and listing on the Hong Kong Exchange in 2023, Adicon is one of the largest independent clinical laboratories in China. In October 2018, private equity Carlyle Group completed its investment in Adicon and has since been the largest single shareholder. Following Carlyle's investment, Adicon quickly stepped up its footprint. It has a testing portfolio of over 4,000 medical diagnostic tests with 36 self-operated laboratories in 2023, compared with 1,800 items and 21 labs in 2018. Currently, esoteric tests account for nearly 60% of its testing portfolio. Esoteric tests require more specialized technologies and/or equipment.
Executives
Cap V General Partner, L.p. 2201 Interest of corporation controlled by you
Cap V, L.l.c. 2201 Interest of corporation controlled by you
Carlyle Asia Partners V, L.p. 2201 Interest of corporation controlled by you
Carlyle Holdings Ii Gp L.l.c. 2201 Interest of corporation controlled by you
Carlyle Holdings Ii L.l.c. 2201 Interest of corporation controlled by you
Cg Subsidiary Holdings L.l.c. 2201 Interest of corporation controlled by you
Pearl Group Limited 2101 Beneficial owner
Tc Group Cayman Investment Holdings L.p. 2201 Interest of corporation controlled by you
Tc Group Cayman Investment Holdings Sub L.p. 2201 Interest of corporation controlled by you
The Carlyle Group Inc. 2201 Interest of corporation controlled by you
Lin Feng
Mega Stream Limited
Trident Trust Company (hk) Limited 2301 Trustee
Ingenuity Capital Holdings Limited 2201 Interest of corporation controlled by you
Corelink Group Limited